Publication:
Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?

Simple item page
dc.contributor.authorsBasaran, Gul; Agaoglu, Fulya; Basaran, Mert
dc.date.accessioned2022-04-25T00:10:33Z
dc.date.accessioned2026-01-11T17:44:55Z
dc.date.available2022-04-25T00:10:33Z
dc.date.issued2010
dc.identifier.doi10.1200/JCO.2010.29.0304
dc.identifier.eissn1527-7755
dc.identifier.issn0732-183X
dc.identifier.pubmed20606082
dc.identifier.urihttps://hdl.handle.net/11424/263709
dc.identifier.wosWOS:000281909700049
dc.languageeng
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.relation.ispartofJOURNAL OF CLINICAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectRADIATION-THERAPY
dc.subjectABVD CHEMOTHERAPY
dc.subjectRADIOTHERAPY
dc.subjectDISEASE
dc.subjectTRIAL
dc.titleDoxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?
dc.typeother
dc.type.subletter
dspace.entity.typePublication
oaire.citation.endPageE486
oaire.citation.issue27
oaire.citation.startPageE485
oaire.citation.titleJOURNAL OF CLINICAL ONCOLOGY
oaire.citation.volume28

Files

Collections

Araştırma Çıktıları